Cue Biopharma, Inc. (NASDAQ: CUE) is a Healthcare company (Biotechnology) with a market capitalization of $92M. The Maz Rating grades it against the other companies in its sector.
Cue Biopharma, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $12.60, Cue Biopharma, Inc. trades at 2.9x sales. Over the last twelve months it generated about $32M of revenue and a net loss of $192M. It runs a gross margin of 99.5%, an operating margin of -387.8% and a net margin of -579.9%. It shows return on equity of -1641.9%, return on invested capital of -238.5% and a free cash flow yield of -49.0%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 0.00. Over the past 52 weeks the share price ranged from $4.97 to $45.50, with a beta of 2.81.
Cue Biopharma, Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 9 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.